RecruitingNCT04587388

Towards Personalized Medicine for Refractory/Relapsed Follicular Lymphoma Patients: the Cantera/Lupiae Registry

Sponsor

European Hematology Association - Lymphoma Group

Enrollment

500 participants

Start Date

May 22, 2019

Study Type

OBSERVATIONAL

Conditions

Follicular Lymphoma Relapsed/Refractory Follicular Lymphoma

Summary

The optimal treatment strategy in patients with early progressive disease is not well known. In recent years, novel insights into the biology of Follicular Lymphoma (FL), and especially the role of the microenvironment, have resulted in the development of multiple novel treatment modalities. These new agents may ultimately improve the outlook for patients with FL with an unfavorable course, but for the development of the optimal therapeutic strategy, knowledge on the clinical and biological determinants of early refractory FL is needed.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

Patients with initial diagnosis of follicular lymphoma, refractory/relapsed/transformed after first line therapy;
All stages at the time of relapse;
Histological grade 1-3a at the time of initial diagnosis;
Age over 18 years;
Availability of clinical data, including baseline information, comorbidities, data on disease localization, laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating as requested
Diagnostic material available for review;
Written informed consent.

Exclusion Criteria1

• Age \< 18 years

Locations(11)

Klinički Bolnički Centar Split

Split, Croatia

AOU Città della Salute e della Scienza di Torino

Torino, Italy

Academic Medical Center

Amsterdam, Netherlands

University Medical Center Groningen

Groningen, Netherlands

Instituto Português de Oncologia Francisco Gentil

Lisbon, Portugal

Hospital Clinic de Barcelona

Barcelona, Spain

Hospital 12 de Octubre

Madrid, Spain

Hospital Jose Maria Morales Meseguer

Murcia, Spain

Hospital de Son Llàtzer

Palma, Spain

Hospital Universitario de Salamanca

Salamanca, Spain

Kiev National Cancer Institute

Kiev, Ukraine

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04587388

Related Trials

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716120 locations

A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

NCT05100862277 locations